| Ytd | 49.55% | |
| 1y | 77.37% |
| Open | 25.07 | Prev Close | 25.00 | Low | 24.59 | High | 25.29 | Mkt Cap | 3.92B |
| Vol | 0.00 | Avg Vol | 1.85M | EPS | -2.88 | P/E | -8.57 | Forward P/E | -10.31 |
| Beta | 1.01 | Short Ratio | 7.65 | Inst. Own | 105.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 23.48 | 200-d Avg | 20.07 | 1yr Est | 34.50 |
DNLI News
On June 30, 2026, Baillie Gifford (Trades, Portfolio) executed a reduction of 106,249 shares in Dena
California State Teachers Retirement System increased its position in shares of Denali Therapeutics
Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and
Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript
Denali Therapeutics NASDAQ: DNLI reported $3.6 million in net product revenue from AVLAYAH during th
Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.68 per share versus the Zacks C
Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net
SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNL
Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fr
JP Morgan analyst Jessica Fye reinstates Denali Therapeutics (NASDAQ:DNLI) with a Overweight and
SOUTH SAN FRANCISCO, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNL
Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partners
DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to adv
SOUTH SAN FRANCISCO, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNL
Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Denali Therapeutics (DNLI) maintains a "Strong Buy" rating following FDA Accelerated Approval of AVL
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt d
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through s
Denali Therapeutics NASDAQ: DNLI is seeing early commercial interest for its first approved drug, AV
Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transc
Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatme
Denali shares fall after Takeda exits DNL593 deal; company regains full rights and targets Phase 1/2
Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer
FDA placed hold on Denali's drug for Pompe disease, requesting changes to protocol. No additiona
Denali Therapeutics Inc. (NASDAQ:DNLI) and Royalty Pharma plc (NASDAQ:RPRX) today announced a $275 m
On Tuesday, 647 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
During Tuesday's session, 275 companies made new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week
On Friday, 431 companies hit new 52-week lows.
On Wednesday, 160 companies hit new 52-week lows.
On Tuesday, 242 companies hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.
During Tuesday's morning session, 342 companies made new 52-week highs.
Monday's morning session saw 240 companies set new 52-week highs.
During the morning session on Monday, 243 stocks hit new 52-week highs.
This morning 67 companies set new 52-week highs.
This morning 118 companies reached new 52-week highs.
Stocks That Hit 52-Week Lows On Thursday
68 Biggest Movers From Yesterday
75 Biggest Movers From Yesterday